Arno Therapeutics (ARNI) Enters into Collaboration with Veridex to Develop Diagnostic Test
Arno Therapeutics, a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer, has signed an agreement with Veridex, LLC, a Johnson & Johnson company, for the development of a diagnostic test to help identify patients that could potentially benefit from treatment with anti-progestinssuch asonapristone, ArnoTherapeutics’ orally administered, investigational type 1 progestin receptor antagonist. The collaboration will allow Arno Therapeutics to utilize CELLSEARCH®, Veridex's proprietary technology that uses an advanced cell separation technique to isolate CTCs and further analyze the cells for the presence of APR. The CELLSEARCH® CTC System is the first and only standardized, FDA-cleared, semi-automated system…